RecruitingPhase 2NCT04440280

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Sponsor

Massachusetts Eye and Ear Infirmary

Enrollment

45 participants

Start Date

Sep 16, 2020

Study Type

INTERVENTIONAL

Conditions

Fuchs' Endothelial Corneal Dystrophy

Summary

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called N-acetyl cysteine (NAC) 10% solution, a drug called N-acetyl cysteine (NAC) 20% solution, and others for people with fuchs' endothelial corneal dystrophy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.